List view / Grid view
12 February 2014 | By Pfizer
Pfizer agrees with the recommendation of the joint meeting of the FDA Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee...
5 February 2014 | By Pfizer
Agreement to combine Merck’s investigational anti-PD-1 and key Pfizer oncology assets...
3 February 2014 | By Pfizer
Clinical benefit demonstrated for potential first-in-class CDK 4 and 6 inhibitor...
27 January 2014 | By Pfizer
An Ongoing, Third Phase 3 Trial is Evaluating Dacomitinib in First-Line in EGFR-Mutant NSCLC...
23 January 2014 | By Pfizer Inc
Pfizer Inc. announced top-line results from a Phase 3 study of investigational agent ALO-02 in patients with moderate-to-severe chronic low back pain...
8 November 2013 | By Pfizer
The primary endpoint of the study was not achieved as there was not a statistically significant difference in renal function improvement...
28 October 2013 | By Bristol-Myers Squibb
“Fibs or Facts” educational program launches today to help raise up to $25,000 for National Stroke Association...
The study met its primary endpoint, showing a statistically significant greater reduction in fibromyalgia pain...
17 October 2013 | By Pfizer
Label now includes information on use of Prevenar 13 in preterm infants, children and adolescents with sickle cell disease...
9 October 2013 | By Pfizer
The brand’s latest innovation provides eight hours of moisture and contains advanced ingredient...
9 October 2013 | By Pfizer Inc.
“We are excited to see progress in our development program in psoriasis..."
3 October 2013 | By Pfizer Inc.
“The approval of DUAVEE, an important, novel and effective treatment, presents a new opportunity for women..."
25 September 2013 | By Pfizer
Long-term safety and efficacy data of XELJANZ up to five years will be presented at the American College Of Rheumatology 2013 annual meeting...
3 September 2013 | By Pfizer
Data show consistent results in reductions in stroke or systemic embolism, fewer major bleeding events, and reductions in all-cause death...
31 August 2013 | By Pfizer
Results presented at the ESC Congress 2013...
